<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article265</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/NA-ACCORD" style="display:block; margin-bottom:10px;">NA-ACCORD Original</a></li>
<h2><strong>NA-ACCORD</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Timing of Antiretroviral Therapy for HIV-1 Infection and Mortality". The New England Journal of Medicine. 2009. 360:1815-1826. PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does early initiation of antiretroviral therapy improve survival in asymptomatic patients with human immunodeficiency virus (HIV) infection compared to deferred therapy?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds (351 to 500 cells per cubic millimeter or &gt;500 cells per cubic millimeter) significantly improved survival compared with deferred therapy.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
A large observational study involving 17,517 asymptomatic HIV-infected patients assessed the timing of initiation of antiretroviral therapy and its impact on survival. Patients were grouped by CD4+ counts at therapy initiation (either 351-500 cells per cubic millimeter or &gt;500 cells per cubic millimeter), and compared with patients who deferred treatment until CD4+ counts fell below these thresholds. In patients with CD4+ counts of 351-500, deferred therapy increased the risk of death by 69% compared with early initiation. For patients with CD4+ counts &gt;500, deferral increased mortality risk by 94%.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current HIV treatment guidelines recommend initiation of antiretroviral therapy in asymptomatic patients with CD4+ counts less than 350 cells per cubic millimeter, acknowledging the lack of randomized clinical trial data regarding this recommendation.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Two parallel analyses of a multicenter, observational cohort study involving patients from the United States and Canada.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Asymptomatic HIV-infected patients<br/>
- CD4+ count of 351-500 cells per cubic millimeter or &gt;500 cells per cubic millimeter<br/>
- No previous antiretroviral therapy<br/>
- No history of AIDS-defining illness<br/>
<br/>
Exclusion Criteria<br/>
- Not reported<br/>
<br/>
Baseline Characteristics<br/>
- Patients initiating early therapy were slightly older and more likely to be white men.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were classified into two treatment strategies: early initiation of antiretroviral therapy or deferral until CD4+ count decreased below threshold levels.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Risk of death<br/>
<br/>
Secondary Outcomes<br/>
- Not reported<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Observational study design does not eliminate possibility of confounding.<br/>
- The decision to initiate or defer therapy could have been influenced by factors not measured in this study.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
National Institutes of Health and the Agency for Healthcare Research and Quality.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel." JAMA 304(3):321-33.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
